REFERENCES
- Requirements for Submission of In-Vivo Availability, Bioavailability and Bioequivalence. 21 CFR 320.21, Office of the Federal Register, National Archives and Records Administration, Washington, DC 4/99; 191
- Preface to the USP 23. USP 23/NF 18 liii. United States Pharmacopeial Convention Inc., 1/1/95
- Hawi A., Cappola M., Tanguay J. Dissolution Profiles of R-One Bioequivalence Tablet Batches. PD-95-1000/U95-3021. Boehringer Ingelheim Internal Report, 1/18/95
- Rashid A. Bioavailability of Ranitidine HCl Tablets 300 mg. 138-01-10722/U95-3165. Boehringer Ingelheim Internal Report, 3/17/95
- Dissolution (711). USP 23/NF 18. United States Pharmacopeial Convention Inc., 1791–1793, 1/1/95
- Monograph-Ranitidine Tablets. USP 23/NF 18. United States Pharmacopeial Convention Inc., 1360–1361, 1/1/95